MediciNova asthma drug fails trial; shares crash – Reuters

MediciNova asthma drug fails trial; shares crash
Reuters
(Reuters) – Biopharmaceutical company MediciNova Inc said its experimental asthma drug failed to meet the main goal of a second mid-stage trial, sending its shares down as much as 51 percent in extended trade. MediciNova, which is testing MN-221 as a
MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma MarketWatch (press release)
MediciNova (MNOV) Says Results of Phase 2B Trial of MN-221 Didn't Meet Primary StreetInsider.com (subscription)

all 11 news articles »

View full post on asthma – Google News

SkyePharma asthma drug wins European backing – Reuters UK

SkyePharma asthma drug wins European backing
Reuters UK
By Paul Sandle | LONDON (Reuters) – SkyePharma said on Friday its lead product, asthma therapy Flutiform, had been recommended for approval by European regulators, doubling the value of the group's shares. Flutiform was referred to the European
SkyePharma's asthma drug wins European backingLondon South East

all 4 news articles »

View full post on asthma – Google News